Vertex Pharmaceuticals (VRTX) Q2 2024 earnings summary

Executive summary

• Q2 2024 product revenue rose 6% year-over-year to $2.65B, driven by CF franchise, TRIKAFTA/KAFTRIO uptake, and early Casgevy launch.

• Full-year 2024 product revenue guidance increased to $10.65–$10.85B, reflecting confidence in CF growth, Casgevy launches, and pipeline execution.

• Closed $5B Alpine Immune Sciences acquisition, resulting in a $4.4B IPR&D charge and impacting Q2 net results.

• Advanced pipeline with regulatory submissions and FDA priority reviews for vanzacaftor triple (CF) and suzetrigine (acute pain), with PDUFA dates in early 2025.

• Progressed pivotal and late-stage programs in T1D (VX-880), IgA nephropathy (povotacicept), SCD/TDT (Casgevy), and pain portfolio.

Financial highlights

• Q2 2024 product revenue: $2.65B (+6% YoY); U.S. up 7% to $1.61B, ex-U.S. up 5% to $1.03B.

• Q2 net loss: $(3.6)B (GAAP) and $(3.3)B (non-GAAP), driven by $4.4B Alpine IPR&D charge.

• Non-GAAP loss per share: $(12.83) vs. $3.89 EPS in Q2 2023.

• Combined GAAP R&D and SG&A expenses: $1.3B (up from $1.0B YoY); non-GAAP: $978M (up from $928M YoY).

• Cash, cash equivalents, and marketable securities: $10.2B at quarter end, down from $13.7B at year-end due to Alpine acquisition.

Outlook and guidance

• 2024 product revenue guidance raised to $10.65–$10.85B, reflecting continued CF growth and Casgevy launches.

• Non-GAAP R&D and SG&A expense guidance: $4.2–$4.3B; AIPR&D expense guidance: ~$4.6B (includes Alpine charge).

• Non-GAAP effective tax rate for 2024 projected at ~100% due to non-deductible Alpine IPR&D charge.

• Preparing for potential launches of vanzacaftor triple (CF) and suzetrigine (acute pain) in early 2025.

• Cash flows from product sales and current liquidity expected to fund operations for at least the next 12 months.